Hospital

A multicohort analysis reveals that obesity substantially increases hospitalization and mortality risk across diverse infectious diseases.

Pembrolizumab in adjuvant NSCLC therapy can trigger central adrenal insufficiency with vague fatigue, nausea, and hyponatremia.

A pressure vibration device can cut propofol injection pain in patients undergoing surgeries, matching low-dose ketamine without extra adverse events.

Craig Beavers, PharmD, explores new phase 3 evidence on factor XIa inhibitors for secondary stroke prevention, highlighting OCEANIC-STROKE results, safety, and patient selection.

The biosimilar is a cost-effective treatment for patients with conditions caused by cancer treatment.

Joseph Saseen, PharmD, explains how population health strategies and team-based care create new opportunities for pharmacists to identify lipid treatment gaps and lead evidence-based ASCVD prevention.

Telehealth expands physical therapy and pharmacy support.

Explore the balance of ambition and self-care in cancer care, emphasizing curiosity, collaboration, and the importance of sustainable productivity.

ALZ-801, an oral anti–amyloid oligomer therapy, shows cognitive, functional, and brain-volume benefits in the mild cognitive impairment (MCI) stage of Alzheimer disease, with supportive biomarkers and no edema risk.

Collaborative practice agreements let pharmacists speed multiple sclerosis therapy starts, manage labs, and boost adherence—easing provider workload.

Registry data show COVID-era care disruptions cut 1-year cancer survival, adding 17,390 excess deaths—the biggest losses in late-stage and older patients.

Joseph Saseen, PharmD, highlights how pharmacists can close treatment gaps in dyslipidemia by initiating appropriate statin intensity early, using combination therapy when needed, and proactively assessing adherence.

Incretin-based therapies were associated with a lower risk of dementia compared with sulfonylureas in older adults with type 2 diabetes, highlighting potential cognitive benefits relevant to long-term diabetes management.

Study links GLP-1 receptor agonists plus progestin to lower endometrial cancer risk, hinting at new prevention and treatment paths with fewer hysterectomies.

Both formulations were also well-tolerated and withdrawal was rare.

Patients need evidence that reflects real benefit.

Explore emerging evidence on aspirin’s potential role in reducing cancer risk and improving survival.

Pharmacists can use collaborative practice agreements in neurology to manage multiple sclerosis medications, labs, and expand care beyond disease-modifying therapies.

H. pylori requires diagnosis, antibiotic- and acid-suppression-based therapy, and post-treatment eradication confirmation to prevent gastritis and cancer.

The FDA targets mass-marketed compounded GLP-1 drugs, warning of safety risks and deceptive ads as enforcement ramps up for weight-loss injectables.

The FDA declines to review Moderna’s mRNA flu vaccine filing over comparator choice, despite positive phase 3 results.

FDA approval expands pembrolizumab (Keytruda) for PD‑L1+ platinum‑resistant ovarian cancer, pairing with paclitaxel ± bevacizumab to improve survival outcomes.

Host Craig Beavers explores why US blood pressure control still lags despite proven treatments.

Intranasal ketamine may remain a potentially viable treatment method for acute pain.

Bangladesh reports fatal Nipah case linked to raw date palm sap; experts say spread stays limited as vaccines and rapid tests advance.

DPYD Testing reshapes oncology dosing for 5‑FU/capecitabine to prevent toxicity and personalize chemotherapy.

Pharmacists unpack CAR T-cell therapy in acute lymphoblastic leukemia, spotlighting obecabtagene autoleucel data and toxicity tips.